Progress in neoadjuvant therapy for gastric cancer.

Gastric cancer is one of the most common malignant tumor types in the world and the majority of patients have already reached the advanced stage at the time of initial diagnosis, owing to the subtle symptoms of gastric cancer in the early stage and the low rate of screening in the population. Surgical resection is one of the main treatments for advanced gastric cancer; however, the efficacy of surgery is limited by factors such as low radical resection rate and high distant metastasis rate. A large number of clinical trials have indicated that neoadjuvant therapy (NAT), which consists of neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy and NAT combined with targeted therapy, may improve the therapeutic effect and prognosis of patients to different degrees. However, the benefit of NAT remains controversial due to the heterogeneity of clinical trials and gastric cancer itself. The present review summarizes the main research progress and key breakthrough of NAT for advanced gastric cancer and discusses its prospects.

A poor prognosis in human hepatocellular carcinoma is associated with low expression of DPP4.

This study aimed to explore the prognostic role of dipeptidyl peptidase 4 (DPP4) expression in hepatocellular carcinoma (HCC). DPP4 expression was measured in formalin-fixed paraffin-embedded specimens that were gathered from 327 HCC patients. Immunohistochemistry analyses were utilized to examine DPP4 expression characteristics and prognostic values (overall survival (OS) and time to recurrence) of DDP4 in HCC tissues. In addition, a patient-derived xenograft (PDX) model was used to assess the correlation between DPP4 expression and tumor growth in vivo. DPP4 was expressed in low levels in HCC tissues in contrast to paired peritumoral tissues (38 cases were down-regulated in a total of 59 cases, 64.4%. P=0.0202). DPP4 expression was significantly correlated with TNM stage (P=0.038), tumor number (P=0.035), and vascular invasion (P=0.024), and significantly reduced in patients who were in TNM stages II and III-V, with multiple tumors, and with microvascular invasion compared to patients with TNM stage I, single tumor, and no microvascular invasion. Notably, HCC tissues with low expression of DPP4 had poor OS (P=0.016) compared with HCC tissues with high expression of DPP4, and results from PDX model showed that tumor growth was significantly faster in HCC patients that lowly expressed DPP4 compared to those with highly expressed DPP4. Our findings suggested that low levels of DPP4 could impact the aggressiveness of HCC and contribute to a poor prognosis.

A poor prognosis in human hepatocellular carcinoma is associated with low expression of DPP4

This study aimed to explore the prognostic role of dipeptidyl peptidase 4 (DPP4) expression in hepatocellular carcinoma (HCC). DPP4 expression was measured in formalin-fixed paraffin-embedded specimens that were gathered from 327 HCC patients. Immunohistochemistry analyses were utilized to examine DPP4 expression characteristics and prognostic values (overall survival (OS) and time to recurrence) of DDP4 in HCC tissues. In addition, a patient-derived xenograft (PDX) model was used to assess the correlation between DPP4 expression and tumor growth in vivo. DPP4 was expressed in low levels in HCC tissues in contrast to paired peritumoral tissues (38 cases were down-regulated in a total of 59 cases, 64.4%. P=0.0202). DPP4 expression was significantly correlated with TNM stage (P=0.038), tumor number (P=0.035), and vascular invasion (P=0.024), and significantly reduced in patients who were in TNM stages II and III-V, with multiple tumors, and with microvascular invasion compared to patients with TNM stage I, single tumor, and no microvascular invasion. Notably, HCC tissues with low expression of DPP4 had poor OS (P=0.016) compared with HCC tissues with high expression of DPP4, and results from PDX model showed that tumor growth was significantly faster in HCC patients that lowly expressed DPP4 compared to those with highly expressed DPP4. Our findings suggested that low levels of DPP4 could impact the aggressiveness of HCC and contribute to a poor prognosis.

[Clinical Efficacy of Radiotherapy Combined with Chemotherapy for Primary Mediastinal Large B-cell Lymphoma].

OBJECTIVE: To explore the clinical efficacy of radiotherapy combined with chemotherapy for patients with primary mediastinal large B-cell lymphoma(PMLBCL). METHODS: A total of 34 cases of PMLBCL were treated by radiotherapy combined with chemotherapy(radio-chemotherapy group), 28 cases of PMLBCL were treated by chemotherapy alone (single chemotherapy group as control). The clinical efficacy, side effects, long-term survival of the two group patients were compared. RESULTS: The overall remission(OR) in the radio-chemotherapy group were higher than that in single chemotherapy group (P<0.05); the blood toxicity reaction, mucositis, radiation dermatitis in radio-chemotherapy group were higher than those in single chemotherapy group (P<0.05); the progress free survival(PFS) for 1 year in radio-chemotherapy group was higher than that in the single chemotherapy group (P<0.05), the local control (LC), PFS for 3 years in the radio-chemotherapy group were higher than those in the single chemotherapy group (P<0.05), the LC, OS, PFS for 5 years in the radio-chemotherapy group were higher than those in the single chemotherapy group (P<0.05). CONCLUSION: The radiotherapy combined with chemotherapy has good clinical efficacy for patients with primary mediastinal large B-cell lymphoma, it has high rate of progression-free survival, it can be used as optimed scheme for treating PMLBCL, but the complications resulting from radio-chemotherapy should be prevented.

[Clinical efficacy of radiotherapy and chemotherapy combined with surgical treatment for the patients with primay mediastinal B-cell lymphoma].

OBJECTIVE: This study was to investigate the clinical efficacy of radiotherapy and chemotherapy combined with surgical treatment for treatment of patients with primay mediastinal B-cell lymphoma. METHODS: A total of 62 patients with primay mediastinal B-cell lymphoma was selected, out of them 26 patients received radiotherapy and che-motherapy were selected as A group, other 36 patients received radiotherapy and chemotherapy combined with surgical treatment and were selected as B group. Clinical efficacy were observed and compared after treatment. RESULTS: In A group 5 patients achieved complete remission (CR), 5 patients achieved partial remission (PR), the total remission rate of A group was 27.8%; in B grouop, 13 patients achieved complete remission (CR), 10 patients achieved PR, the total remission rate of B group was 63.9%. The average survival time of patients in B group was 57.244 months, and the average survival time of patients in A group was 55.541 months, the former was higher than latter. The 5 years survical rate of patients in A group was 57.7%, and the 5 years survival rate of patients in B group was 80.6%, the latter was significantly higher than former. CONCLUSIONS: Radiotherapy and chemotherapy combined with surgical treatment for patients with primay media-stinal B-cell lymphoma has been confirmed to be effective, and may be used in clinic.

Diethyl 2,2'-bis-(hy-droxy-imino)-3,3'-(hydrazinediyl-idene)dibutano-ate.

Each mol-ecule of the title compound, C(12)H(18)N(4)O(6), is located on an inversion centre at the mid-point of the central N-N bond. The azo groups C=N of the Schiff base group have an E conformation and the azo groups in the oxime C=N-O groups have a Z conformation. O-H⋯O hydrogen bonds link neighbouring mol-ecules into infinite monolayers perpendicular to the a axis.

2-[(E)-(2-Hy-droxy-naphthalen-1-yl)methyl-idene-amino]-isoindoline-1,3-dione.

The title compound, C(19)H(12)N(2)O(3), has two independent mol-ecules (A and B) in the asymmetric unit. There is an intra-molecular O-H⋯N hydrogen bond in each mol-ecule. The mean planes of the naphthalene [maximum deviations = 0.024 (3) and 0.030 (3) Šin A and B, respectively] and the isoindoline units [maximum deviations 0.009 (3) and 0.008 (3) Šin A and B, respectively] are almostly coplanar, with dihedral angles of 4.25 (9) ad 3.84 (9)° in mol-ecules A and B, respectively. The two independent mol-ecules are connected by π-π inter-actions [centroid-centroid distances 3.5527 (19) and 3.5627 (19) Å]. In the crystal, the A+B pairs are further connected via π-π inter-actions [centroid-centroid distances = 3.693 (2)-3.831 (2) Å], leading to the formation of columns propagating along the a-axis direction. The columns are linked via C-H⋯O inter-actions, leading to the formation of a three-dimensional network.

4,4'-Bis(2,2-diphenyl-vin-yl)-1,1'-biphen-yl.

The title mol-ecule, C(40)H(30), lies on an inversion center. The two unique phenyl rings form dihedral angles of 51.98 (8) and 67.58 (8)° with the essentially planar biphenyl unit [maximum deviation = 0.0360 (14) Å].